Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management

Expert Review of Anticancer Therapy

Volumn 9, Issue 8, 2009, Pages 1145-1157

  Thomas, David M ^b   O'Sullivan, Brian ^c   Gronchi, Alessandro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Chemotherapy; Prognosis; Radiotherapy; Retroperitoneal sarcoma; Sarcoma; Surgery; Survival

Indexed keywords

CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; IFOSFAMIDE; IMATINIB; MISONIDAZOLE; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P53; TRABECTEDIN;

ADJUVANT THERAPY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; EWING SARCOMA; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTRAOPERATIVE RADIOTHERAPY; LEIOMYOSARCOMA; LIPOSARCOMA; NEUROECTODERM TUMOR; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; PERIPHERAL NEUROPATHY; RADIATION DOSE; RETROPERITONEAL SARCOMA; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURGICAL APPROACH; SYNOVIAL SARCOMA; TISSUE TYPES;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHILD; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; RETROPERITONEAL NEOPLASMS; SARCOMA;

EID: 70350637496     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.77     Document Type: Review

References (93)

1. WHO. Pathology and genetics of tumours of soft tissue and bone. Fletcher CD, Unni KK, Mertens F (Eds). IARC Press, Lyons, (2002).
2. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J. Clin. Oncol. 20(3), 791-796 (2002).
3. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann. Surg. 228(3), 355-365 (1998). (Pubitemid 30191698)
4. Henricks WH, Chu YC, Goldblum JR, Weiss SW. Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. Am. J. Surg. Pathol. 21(3), 271-281 (1997).
5. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J. Clin. Oncol. 19(12), 3045-3050 (2001). (Pubitemid 32565442)
6. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 369(9574), 1731-1741 (2007).
7. Lal DR, Su WT, Wolden SL et al. Results of multimodal treatment for desmoplastic small round cell tumors. J. Pediatr. Surg. 40(1), 251-255 (2005).
8. Fritz B, Schubert F, Wrobel G et al. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res. 62(11), 2993-2998 (2002). (Pubitemid 34602383)
9. Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet. Cytogenet. 155(1), 1-24 (2004).
10. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6(12), 909-923 (2006). (Pubitemid 44862676)
11. Pilotti S, Della Torre G, Lavarino C et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J. Pathol. 181(1), 14-24 (1997). (Pubitemid 27099769)
12. Forus A, Bjerkehagen B, Sirvent N et al. A well-differentiated liposarcoma with a new type of chromosome 12-derived markers. Cancer Genet. Cytogenet. 131(1), 13-18 (2001). (Pubitemid 33081152)
13. Mariani O, Brennetot C, Coindre JM et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 11(4), 361-374 (2007). (Pubitemid 46518313)
14. Antonescu CR, Elahi A, Healey JH et al. Monoclonality of multifocal myxoid liposarcoma: confirmation by analysis of TLS-CHOP or EWS-CHOP rearrangements. Clin. Cancer Res. 6(7), 2788-2793 (2000). (Pubitemid 30482118)
15. Fiore M, Grosso F, Lo Vullo S et al. Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution. Cancer 109(12), 2522-2531 (2007). (Pubitemid 46906472)
16. Schwab JH, Boland P, Guo T et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann. Surg. Oncol. 14(4), 1507-1514 (2007). (Pubitemid 46536828)
17. Pitson G, Robinson P, Wilke D et al. Radiation response: an additional unique signature of myxoid liposarcoma. Int. J. Radiat. Oncol. Biol. Phys. 60(2), 522-526 (2004). (Pubitemid 39233472)
18. Guadagnolo BA, Zagars GK, Ballo MT et al. Excellent local control rates and distinctive patterns of failure in myxoid liposarcoma treated with conservation surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70(3), 760-765 (2008).
19. Perez-Losada J, Pintado B, Gutierrez-Adan A et al. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 19(20), 2413-2422 (2000). (Pubitemid 30323474)
20. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19(52), 6015-6022 (2000). (Pubitemid 32040990)
21. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M et al. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARγ and C/EBPα and activating eIF4E. PLoS ONE 3(7), e2569 (2008).
22. Perez-Mancera PA, Perez-Losada J, Sanchez-Martin M et al. Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice. Oncogene 21(11), 1679-1684 (2002). (Pubitemid 34259031)
23. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11(4), 375-388 (2007). (Pubitemid 46518310)
24. Gerald WL, Haber DA. The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin. Cancer Biol. 15(3), 197-205 (2005).
25. Tirode F, Laud-Duval K, Prieur A et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11(5), 421-429 (2007). (Pubitemid 46680428)
26. Keller C, Arenkiel BR, Coffin CM et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18(21), 2614-2626 (2004). (Pubitemid 39453101)
27. Stojadinovic A, Leung DH, Hoos A et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann. Surg. 235(3), 424-434 (2002). (Pubitemid 34183894)
28. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop. Relat. Res. (153), 106-120 (1980).
29. Canter RJ, Qin LX, Ferrone CR et al. Why do patients with low-grade soft tissue sarcoma die? Ann. Surg. Oncol. 15(12), 3550-3560 (2008).
30. Gronchi A, Casali PG, Fiore M et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 100(11), 2448-2455 (2004). (Pubitemid 38657895)
31. Gronchi A, Casali PG, Mariani L et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J. Clin. Oncol. 23(1), 96-104 (2005). (Pubitemid 41702627)
32. Stoeckle E, Coindre JM, Bonvalot S et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer 92(2), 359-368 (2001). (Pubitemid 32664443)
33. Zagars GK, Ballo MT, Pisters PW et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 225 patients. Cancer 97(10), 2530-2543 (2003).
34. Anaya DA, Lev DC, Pollock RE. The role of surgical margin status in retroperitoneal sarcoma. J. Surg. Oncol. 98(8), 607-610 (2008).
35. Bonvalot S, Rivoire M, Castaing M et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J. Clin. Oncol. 27(1), 31-37 (2009). • Large retrospective multicenter analysis on primary retroperitoneal sarcoma treated by different surgical approaches, which shows an important improvement in local control for patients operated more aggressively.
36. Gronchi A, Lo Vullo S, Fiore M et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J. Clin. Oncol. 27(1), 24-30 (2009). • Large monoinstitutional retrospective analysis on retroperitoneal soft-tissue sarcoma, which shows an important improvement in local control for patients being operated in a more recent period when a more aggressive approach was undertaken.
37. Lahat G, Anaya DA, Wang X et al. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann. Surg. Oncol. 15(6), 1585-1593 (2008).
38. Pisters PW. Resection of some, but not all, clinically uninvolved adjacent viscera as part of surgery for retroperitoneal soft tissue sarcomas. J. Clin. Oncol. 27(1), 6-8 (2009).
39. Gerrand CH, Wunder JS, Kandel RA et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J. Bone Joint Surg. Br. 83(8), 1149-1155 (2001). • Retrospective analysis on the significance of an expected positive margin on local outcome in extremity soft-tissue sarcoma. A planned in advance positive margin does not compromise local control providing adequate radiotherapy is administered.
40. Gronchi A, Miceli R, Fiore M et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann. Surg. Oncol. 14(5), 1583-1590 (2007). (Pubitemid 46791007)
41. Mussi C, Collini P, Miceli R et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer 113(7), 1657-1665 (2008).
42. Yeh JJ, Singer S, Brennan MF, Jaques DP. Effectiveness of palliative procedures for intra-abdominal sarcomas. Ann. Surg. Oncol. 12(12), 1084-1089 (2005). (Pubitemid 41660685)
43. Park JO, Qin LX, Prete F, Brennan MF, Singer S. Growth rate predicts outcome in locally recurrent retroperitoneal sarcoma. Proceedings of the 13th Annual Meeting of the Connective Tissue Oncology Society, Seattle, WA, USA 31 October-3 November (2007) (Abstract 382).
44. Adjuvant-chemotherapy: adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. sarcoma meta-analysis collaboration. Lancet 350(9092), 1647-1654 (1997).
45. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3), 573-581 (2008). • This paper heroically represents the apotheosis of a 20-year effort to demonstrate a benefit (or lack thereof) for adjuvant chemotherapy for soft-tissue sarcomas.
46. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348(8), 694-701 (2003).
47. Karavasilis V, Seddon BM, Ashley S et al. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112(7), 1585-1591 (2008).
48. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8(7), 595-602 (2007). (Pubitemid 46995623)
49. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23(3), 576-584 (2005). • This report established the role of trabectidin as an effective systemic therapy for some subtypes of soft-tissue sarcomas. (Pubitemid 46224235)
50. George S, Merriam P, Maki RG et al. Multicenter Phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J. Clin. Oncol. 27(19), 3154-3160 (2009).
51. Maki RG, D'Adamo DR, Keohan ML et al. Phase II study of Sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133-3140 (2009).
52. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20(12), 2824-2831 (2002). • This report established the role of a novel drug combination (docetaxel and gemcitabine) in advanced soft-tissue sarcomas, to add to the long established pair of doxorubicin and ifosfamide. (Pubitemid 34651511)
53. Bleyer A, Barr R, Hayes-Lattin B et al. The distinctive biology of cancer in adolescents and young adults. Nat. Rev. Cancer 8(4), 288-298 (2008).
54. Khamly KK, Thursfield VJ, Desai J et al. Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int. J. Cancer 125(2), 426-431 (2009).
55. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin. Ther. Targets 12(5), 589-603 (2008).
56. Stuart-Buttle CE, Smart CJ, Pritchard S, Martin D, Welch IM. Desmoplastic small round cell tumour: a review of literature and treatment options. Surg. Oncol. 17(2), 107-112 (2008).
57. Raney RB, Maurer HM, Anderson JR et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5(1), 9-15 (2001).
58. Sindelar WF, Kinsella TJ, Chen PW et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch. Surg. 128(4), 402-410 (1993).
59. Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res. 9(6), 1941-1956 (2003).
60. Pisters PW. Retroperitoneal sarcomas - an SOS to colleagues in Europe. Ann. Surg. Oncol. 14(6), 1787-1789 (2007).
61. Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer 106(7), 1610-1616 (2006).
62. Catton CN, O'Sullivan B, Kotwall C et al. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 29(5), 1005-1010 (1994). • This was the first report to identify that radiotherapy delivered postperatively appeared to have the potential to delay the time to local recurrence in retroperitoneal sarcoma although the strategy appeared unable to impact on the cure of these patients in long-term follow-up. (Pubitemid 24278967)
63. Ballo MT, Zagars GK, Pollock RE et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 158-163 (2007).
64. Gilbeau L, Kantor G, Stoeckle E et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother. Oncol. 65(3), 137-143 (2002). (Pubitemid 35441044)
65. Pisters PW, O'Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr. Opin. Oncol. 14(4), 400-405 (2002). (Pubitemid 34747975)
66. Gieschen HL, Spiro IJ, Suit HD et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 50(1), 127-131 (2001). • Provides long-term results of patients treated with preoperative radiotherapy, many of whom also received intraoperative radiotherapy (IORT). The authors concluded that the preoperative strategy was well tolerated and provided unusually favorable outcomes but seemed also inclined to attribute these benefits to the use of IORT which was delivered in a selective manner.
67. Jones JJ, Catton CN, O'Sullivan B et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann. Surg. Oncol. 9(4), 346-354 (2002). • This report of a prospective trial identified that preoperative radiotherapy showed extremely good tolerance to preoperative radiotherapy despite very large treatment volumes and that patients treated for primary presentations fared dramatically better than those treated for recurrence. (Pubitemid 34496722)
68. Petersen IA, Haddock MG, Donohue JH et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 52(2), 469-475 (2002).
69. Pisters PW, Ballo MT, Fenstermacher MJ et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J. Clin. Oncol. 21(16), 3092-3097 (2003).
70. Pawlik TM, Pisters PW, Mikula L et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann. Surg. Oncol. 13(4), 508-517 (2006).
71. O'Sullivan B, Ward I, Haycocks T, Sharpe M. Techniques to modulate radiotherapy toxicity and outcome in soft tissue sarcoma. Curr. Treat. Options Oncol. 4(6), 453-464 (2003). (Pubitemid 36133816)
72. Bossi A, De Wever I, Van Limbergen E, Vanstraelen B. Intensity modulated radiation-therapy for preoperative posterior abdominal wall irradiation of retroperitoneal liposarcomas. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 164-170 (2007). (Pubitemid 44959496)
73. Koshy M, Landry JC, Lawson JD et al. Intensity modulated radiation therapy for retroperitoneal sarcoma: a case for dose escalation and organ at risk toxicity reduction. Sarcoma 7(3-4), 137-148 (2003). (Pubitemid 38091191)
74. Tzeng CW, Fiveash JB, Popple RA et al. Preoperative radiation therapy with selective dose escalation to the margin at risk for retroperitoneal sarcoma. Cancer 107(2), 371-379 (2006).
75. Musat E, Kantor G, Caron J et al. Comparison of intensity-modulated postoperative radiotherapy with conventional postoperative conformal radiotherapy for retroperitoneal sarcoma. Cancer Radiother. 8(4), 255-261 (2004). (Pubitemid 39278303)
76. Pezner RD, Liu A, Han C et al. Dosimetric comparison of helical tomotherapy treatment and step-and-shoot intensity-modulated radiotherapy of retroperitoneal sarcoma. Radiother. Oncol, 81(1), 81-87 (2006). (Pubitemid 44540228)
77. White JS, Biberdorf D, DiFrancesco LM, Kurien E, Temple W. Use of tissue expanders and pre-operative external beam radiotherapy in the treatment of retroperitoneal sarcoma. Ann. Surg. Oncol. 14(2), 583-590 (2007). (Pubitemid 46178333)
78. Mikula LA, Ridgway PF, Catton CN et al. Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma. Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society London, UK, 13-15 November, 2008 (Abstract 35038).
79. Yoon SS, Chen Y-L, Kirsch DG et al. Proton beam, intensity modulated, and/or intra-operative radiation therapy combined with aggressive anterior surgical resection for retroperitoneal and pelvic sarcomas. Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society, London, UK, 13-15 November, 2008 (Abstract 34806).
80. Fuser JL, Thomas JM, Hayes A, Ashley S, Saran F. Definitive radiotherapy for inoperable, intermediate and high grade retroperitoneal soft tissue sarcoma. Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society London, UK, 13-15 November, 2008 (Abstract 34949).
81. Warren-Oseni K, Lee YK, Hansen VN, Saran FH. Dose escalation in the treatment of retroperitoneal soft tissue sarcomas. Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society, London, UK, 13-15 November, 2008 (Abstract 35027).
82. Stoeckle E, Kantor G, Dejean C et al. Preoperative high-dose (54 Gy) helicoidal tomotherapy plus surgery in retroperitoneal liposarcoma: a feasibility study. Proceedings of the 14th Annual Meeting of the Connective Tissue Oncology Society London, UK, 13-15 November, 2008 (Abstract 35155).
83. Goodman KA, Wolden SL, La Quaglia MP, Kushner BH. Whole abdominopelvic radiotherapy for desmoplastic small round-cell tumor. Int. J. Radiat. Oncol. Biol. Phys. 54(1), 170-176 (2002).
84. Aguilera D, Hayes-Jordan A, Anderson P et al. Outpatient and home chemotherapy with novel local control strategies in desmoplastic small round cell tumor. Sarcoma 2008, 261589 (2008). (Pubitemid 352000423)
85. Jahraus CD, Glisson SD, St Clair WH. Treatment of desmoplastic small round cell tumor with image-guided intensity modulated radiation therapy as a component of multimodality treatment. Tumori 91(3), 253-255 (2005).
86. Oertel S, Niethammer AG, Krempien R et al. Combination of external-beam radiotherapy with intraoperative electron-beam therapy is effective in incompletely resected pediatric malignancies. Int. J. Radiat. Oncol. Biol. Phys. 64(1), 235-241 (2006). (Pubitemid 41831232)
87. Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch. Surg. 138(3), 248-251 (2003).
88. Dalton RR, Donohue JH, Mucha P Jr. et al. Management of retroperitoneal sarcomas. Surgery 106(4), 725-732 (1989).
89. Singer S, Corson JM, Demetri GD et al. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann. Surg. 221(2), 185-195 (1995).
90. van Doorn RC, Gallee MP, Hart AA et al. Resectable retroperitoneal soft tissue sarcomas: the effect of extent of resection and postoperative radiation therapy on local tumor control. Cancer 73(3), 637-642 (1994).
91. Kilkenny JW 3rd, Bland KI, Copeland EM 3rd. Retroperitoneal sarcoma: the University of Florida experience. J. Am. Coll. Surg. 182(4), 329-339 (1996).
92. Hassan I, Park SZ, Donohue JH et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann. Surg. 239(2), 244-250 (2004). (Pubitemid 38176359)
93. van Dalen T, Plooij JM, van Coevorden F et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur.J. Surg. Oncol. 33(2), 234-238 (2007). (Pubitemid 46336550)